μ Opioid Receptor Gene as a Candidate for the Study of Obsessive Compulsive Disorder with and Without Tics

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 127 B, Issue 1, 2004, Pages 94-96

  Urraca, N ^a,c   Camarena, B ^a   Gomez Caudillo L ^a   Esmer, M C ^b   Nicolini, H ^a  

^a INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^c NONE   (Mexico)

Author keywords

Association study; Obsessive compulsive disorder; TDT; Tics; opioid receptor gene

Indexed keywords

MU OPIATE RECEPTOR; NALOXONE; OPIATE ANTAGONIST; TRAMADOL;

ADULT; ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PATHOGENESIS; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TIC;

EID: 2142700096     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.20170     Document Type: Article

References (34)

1. Berrettini W, Hoehe M, Ferraro T, DeMaria P, Gottheil E. 1997. Human mu opioid receptor gene polymporphisms and vulnerability to substance abuse. Addiction Biol 2:303-308.
2. Billet EA, Riochter MA, Swinson RP. 1997. Investigation of dopamine system genes in obsessive-compulsive disorder. Mol Psychiatry 2:403-406.
3. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong J, Leal S, Tischfield J, Kredd MJ, Yu L. 1998. Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci 95:9608-9613.
4. Camarena B, Cruz C, De La Fuente JR, King N, Nicolini H. 1998. A higher frequency of a low activity-related allele of the MAO-A gene in females with obsessive-compulsive disorder. Psychiatr Genet 8:225-227.
5. Caraveo J, González C, Ramos L. 1991. Concurrent validity of the DIS experiences with psychiatric patient in Mexico City. Hispanice J Behav Sci 13:63-67.
6. Carrion V. 1995. Naltrexone for the treatment of trichotillomania: A case report. J Clin Psychopharmacol 15:444-445.
7. Cruz C, Camarena B, King N, Nicolini H. 1997. Increased prevalence of the seven-repeat variant of the dopamine D4 receptor gene in patients with obsessive-compulsive disorder with tics. Neurosci Lett 231:1-4.
8. Friedman I, Reuven D, Shilony E. 2000. Compulsivity and obsessionality in opioid addiction. J Nerv Ment Dis 188:155-162.
9. Gelernter J, Kranzler H, Cubells J. 1999. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphism: Population studies and allele frequencies in alcohol and drug-dependent subjects. Mol Psychiatry 4:476-483.
10. Goldsmith T, Shapira N, Keck P. 1999. Rapid remission of OCD with tramadol hydrochloride. Am J Psychiatry 156:660-661.
11. Goodman WK, Preice LH, Rasmusen SA. 1989. Efficacy of fluvoxamine in obsessive-compulsive disorder: A double blind comparison with placebo. Arch Gen psychiatry 46:36-43.
12. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GP, Charney DS. 1990. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 45:577-585.
13. Holzer JC, Goodman WK, McDougle CJ, Baer L, Boyarski BK, Leckman JL, Price LH. 1994. Obsessive-compulsive disorder with and without a chronic tic disorder. A comparison of symptoms in 70 patients. Br J Psychiatry 164:469-473.
14. Insel T, Pickar D. 1983. Naloxone administration in obsessive-compulsive disorder: Report of two cases. Am J Psychiatry 140:1219-1220.
15. Karayiorgou M, Altemus M, Galke BL. 1997. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci USA 94:4572-4575.
16. Keuler D, Altemus M, Michelson D, Greenberg B, Murphy D. 1996. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 40:154-156.
17. Kreek MJ. 1973. Medical safety and side effects of methadone in tolerant individual. JAMA 223:665-668.
18. Lahiri DK, Nurnberger JI. 1991. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucl Acids Res 19:5444.
19. Li T, Liu X, Zhu ZH, Ahao J, Hu X, Sham PC, Colier DA. 2000. Association analysis of polymorphisms in the μ opioid gene and heroin abuse in Chinese subjects. Addict Biol 5:181-186.
20. McConville BJ, Norman AN, Fogelson MH, Erenberg G. 1994. Sequential use of opioid antagonists and agonists in Tourette's syndrome (Letter). Lancet 343:601.
21. McDougle CJ, Goodman WK, Lecman JF, Lee NC, Heninger GR, Price LH. 1994a. Haloperidol addition in fluvoxamine refractory obsessive-compulsive disorder. A double blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308.
22. McDougle CJ, Goodman WK, Price LH. 1994b. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry 55(Suppl 3):24-31.
23. Modell JG, Glaser FB, Cyr L, Mountz JM. 1992. Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence. Alcohol Clin Exp Res 16:272-274.
24. Mundo E, Richter M, Sam F, Macciardi F, Kennedy J. 2000. Is the 5-HT1Dβ receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am J Psychiatry 157:1160-1161.
25. Nicolini H, Cruz C, Camarena B. 1996a. DRD2, DRD3, and 5-HT2A receptor genes polymorphisms in obsessive compulsive disorder. Mol Psychiatry 1:461-465.
26. Nicolini H, Herrera K, Páez F, Sánchez de Carmona M, Orozco B, Lodeiro G, de la Fuente JR. 1996b. Traducción al español y confiabilidad de la Escala Yale-Brown para el trastorno obsesivo-compulsivo. Salud Mental 19:13-16.
27. Pauls DL. 1992. The genetics of obsessive-compulsive disorder and Gilles de la Tourette's syndrome. Psychiatr Clin North Am 15:759-766.
28. Sander T, Gscheidel N, Wendel B, Samochowiec J, Smolka M, Rommelspacher H, Schmidt L, Hoehe M. 1998. Human μ-opioid receptor variation and alcohol dependence. Alcohol Clin Exp Res 22:2108-2110.
29. Shapira N, Keck P, Goldsmith T, McConville B, Eis M, McElroy S. 1997a. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 6:170-173.
30. Shapira NA, McConville BJ, Pagnucco ML, Morman AB, Keck PF. 1997b. Novel use of tramadol hydrocholoride in the treatment of Tourette's syndrome (Letter). J Clin Psychiatry 58:174-175.
31. Spielman RS, McGinnis RE, Ewens WJ. 1993. Transmission test for linkage disequilibirum: The insulin gene region and insulin-dependent diabetes (IDDM). Am J Hum Genet 52:506-516.
32. Van Wattum PJ, Chappell PB, Zelerman D, Scahill LD, Leckman JF. 2000. Patterns of response to acute naloxone infusion in Tourette's syndrome. Mov Disord 15:1252-1254.
33. Wang J-B, Johnson PS, Persico AM, Haskins AL, Griffin CA, Uhl Gr. 1994. Human mu opiate receptor: cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett 338:217-222.
34. Warneke L. 1997. A possible new treatment approach to obsessive-compulsive disorder. Can J Psychiatry 42:667-668.